This week's Fierce Biotech is brought to you by BioIVT

Webinar: Safety Considerations for the Development of ADCs

April 30, 2024 | 11:00am ET / 8:00am PT

Explore the promising realm of ADCs in cancer therapy. ADCs deliver cytotoxic drugs via monoclonal antibodies, but concerns about drug release and interactions persist. Despite ongoing development for advanced cancer treatments, regulatory guidance on ADC DDI potential remains unclear.

This webinar will:

• Introduce the novel therapeutic modality of antibody-drug conjugates
• Summarize the mechanism of action and safety considerations for FDA-approved ADCs
• Describe drug interaction potential of ADC payloads currently in the clinic
• Outline experimental strategies for identification of drug interaction potential for novel small molecule ADC payloads